- Human papillomavirus (HPV) infection is the cause of cervical cancer.
- HPV DNA testing is a $1 billion market worldwide.
- Researchers at Yale have identified a specific HPV DNA methylation signature in cervical cells that may have prognostic value for cervical cancer.
- The DNA methylation test described here has the potential to accurately identify HPV DNA‐positive women at minimal risk of developing cervical cancer.
- This test may be able to distinguish patients at minimal versus high-risk of progressing to cancer.
Brandsma, J. L., Harigopal, M., Kiviat, N. B., Sun, Y., Deng, Y., Zelterman, D., … & Feng, Q. (2014). Methylation of twelve CpGs in human papillomavirus type 16 (HPV16) as an informative biomarker for the triage of women positive for HPV16 infection. Cancer Prevention Research, 7(5), 526-533. [Pub Med]